NTRK gene fusions can drive unregulated cell growth and proliferation in a range of cancer types. Recently, these fusions have gained significant focus and attention in precision oncology clinical research.
Next-Generation Sequencing provides the most comprehensive view across a large number of genes and can identify NTRK gene fusions as well as other actionable alterations, with minimal sample tissue needed.
Watch some of our most recent videos. Be sure to check back or subscribe for updates.
This CAP TODAY webinar explains how to make NSCLC biomarker testing a routine part of your care process.
Using the Cancer Genetics Inc. (CGI) testing model and case studies, you'll discover how to practice precision oncology in a way that ensures even challenging samples get tested, so you can achieve the best outcome for as many patients as possible.
If you have any questions after the webinar, be sure to get in touch with our NGS consultants and we'll be happy to provide the answers you need.
Watch this on-demand webinar to learn how the Oncomine Tumor Mutation Load Assay can be used in a pathology laboratory to determine tumor mutation burden, an emerging biomarker, even when you have limited FFPE material.
Experience a three-part webinar series that will explore the successful implementation of NGS liquid biopsy assays across different tumor types.
Thermo Fisher Scientific and its affiliates are not endorsing, recommending, or promoting any use or application of Thermo Fisher Scientific products presented by third parties during this seminar. Information and materials presented or provided by third parties are provided as-is and without warranty of any kind, including regarding intellectual property rights and reported results. Parties presenting images, text and material represent they have the rights to do so.